At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
Indacaterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Repeated-dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients With Persistent Asthma
In Brief
A Phase 2 clinical trial evaluating Indacaterol and Placebo to Indacaterol for Persistent Asthma. Completed, enrolled 191 participants across 30 sites in 6 countries.
Detailed Summary
This study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersistent Asthma
CountriesFrance, Germany, Jordan, Netherlands, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
Primary CompletionJul 2010
First PostedJul 2010
TodayJul 2026
First PostedJul 5, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.0 years ago
Interventions
Indacateroldrug
Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
Placebo to Indacateroldrug
Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.